

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
5 August 2004 (05.08.2004)

PCT


(10) International Publication Number  
**WO 2004/064841 A1**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/517** (74) Agents: **OGILVY RENAULT** et al.; Suite 1600, 1981 McGill College Avenue, Montreal, 10 H3A 2Y3 (CA).
- (21) International Application Number: PCT/CA2004/000096 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 23 January 2004 (23.01.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/441,765 23 January 2003 (23.01.2003) US
- (71) Applicant (for all designated States except US): **SHIRE HOLDING AG** [CH/CH]; Bundersstrasse 5, Zug 6300 (CH).
- (71) Applicant (for MG only): **SHIRE BIOCHEM INC.** [CA/CA]; 275 Armand-frappier Blvd., Laval, Québec H7V 4A7 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **FRANKLIN, Richard** [GB/GB]; 3 Rosedene Gardens, Fleet, Hampshire GU51 4NQ (GB).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:  
— with international search report

[Continued on next page]

(54) Title: FORMULATION AND METHODS FOR THE TREATMENT OF THROMBOCYTHEMIA

Mean plasma concentration-time profiles of anagrelide and Metabolite A after 1mg orally and after dermal application of a saturated solution for 24h.



(57) Abstract: ABSTRACT The present invention provides a method for the treatment or prevention of thrombocytopenia in a patient comprising administering to said patient an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## FORMULATION AND METHODS FOR THE TREATMENT OF THROMBOCYTHEMIA

### FIELD OF THE INVENTION

5

The present invention relates to methods for treating thrombocythemia. The present invention also relates to formulations that are useful for reducing platelet counts.

### BACKGROUND OF THE INVENTION

10

Thrombocythemia is a chronic disorder associated with increased or abnormal production of blood platelets. Since platelets are involved in blood clotting their abnormal production can result in the inappropriate formation of blood clots or in  
15 bleeding, with the consequence that patients' risk of gastrointestinal bleeding, heart attack and stroke is increased.

Anagrelide, a quinazoline derivative phosphodiesterase inhibitor, was first described as a blood platelet anti-aggregative agent, anti-hypertensive agent and  
20 bronchodilator agent in US patent 3,932,407 issued January 13, 1976 and in Reissue patent No. Re.31,617 issued June 26, 1984.

Anagrelide is used currently for the treatment of essential thrombocythemia and various other myeloproliferative disorders. Anagrelide was approved and launched  
25 in 1997 for the treatment of essential thrombocythemia in the US and Canada. In December 1998, the US FDA approved an expanded label for anagrelide; specifically, for the treatment of patients with thrombocythemia secondary to

myeloproliferative disorders, including polycythemia vera (PV) and chronic myelogenous leukemia (CML).

5 Anagrelide is available as 0.5mg and 1.0 mg capsule for oral administration. The most common adverse event observed with anagrelide are related to vasodilatory and positive inotropic effect. These include, headache, diarrhea, palpitations, and tachycardia.

10 It would therefore be desirable to have other formulations that could be used for treating or preventing thrombocythemia.

#### **SUMMARY OF THE INVENTION**

15 As set forth in US patent 3,932,407 issued January 13, 1976 and in Reissue patent No. Re.31,617 June 26, 1984 quinazoline derivative including Anagrelide can be prepared in a solid form for oral and/or parenteral use as blood platelet anti-aggregative agents and/or anti-hypertensive agents and/or bronchodilator agents. However, the patent does not suggest that it would be desirable to avoid the first pass metabolism through the liver in order to reduce some of anagrelide side-  
20 effects when administered orally. The patent also does not suggest that it would be possible or desirable to prepare a transdermal formulation or to use the formulation for the treatment or prevention of thrombocythemia.

25 Without being bound to any theory (an understanding of the mechanism is not necessary to practice the present invention, and the present invention is not limited to any particular mechanism), Applicants believe that certain cardiovascular or inotropic related side effects are associated with a metabolite as a result of first pass through the liver. In accordance with this invention the inventors have found

that surprisingly, certain of these side effects can be reduced by avoiding the first pass liver metabolism.

Applicants have discovered that the transdermal and implant formulations of this invention provides surprising beneficial effects.

Applicant have determined that anagrelide can be effectively administered transdermally.

10 In one embodiment, the formulations of this invention provide consistent dosage of the active ingredient.

In one embodiment, the formulations of this invention achieve sustained plasma concentration of the pharmaceutically active agent.

15

In one embodiment, the formulations of this invention encourage patient compliance.

20 In one aspect, the present invention provides a method for the treatment or prevention of thrombocythemia in a host comprising administering a formulation comprising as an active ingredient an effective amount of anagrelide wherein said formulation is administered by avoiding the first pass liver metabolism.

25 In one aspect, the present invention provides the use of a formulation comprising as an active ingredient an effective amount of anagrelide wherein said formulation is administered by avoiding the first pass liver metabolism for a method for the treatment or prevention of thrombocythemia in a host.

In one aspect, the present invention provides a method for the treatment or prevention of thrombocythemia in a host comprising administering a transdermal or implant formulation comprising as an active ingredient an effective amount of anagrelide.

5

In another aspect, there is provided the use of a formulation in accordance with this invention as a platelet reducing agent.

10

Still, in another aspect, there is provided the use of a formulation in accordance with this invention for treating or preventing thrombocythemia.

15

In a further embodiment, there is provided the use of a formulation in accordance with this invention for the manufacture of a medicament for the treatment of thrombocythemia.

In still another aspect, there is provided a pharmaceutical formulation in accordance with this invention and at least one further therapeutic agent.

#### **DESCRIPTION OF THE FIGURES**

20

Figure 1 represents the mean plasma concentration-time profiles of anagrelide and Metabolite A after 1mg orally and after dermal application of a saturated solution for 24h.

25

Figure 2 represents the effectiveness of continuous low-level exposure to anagrelide.

#### **DETAILED DESCRIPTION OF THE INVENTION**

In one embodiment, formulation of the present invention comprise those wherein the following embodiments are present, either independently or in combination.

Anagrelide has been administered to human subjects as a capsule formulation.

5 Such tablet formulation of anagrelide can be associated with undesired effects when administered to a group of subjects. Surprisingly, the presently claimed transdermal or implant formulations minimize or eliminate such effects while maintaining a consistent, desirable plasma concentration of the pharmacologically active agent.

10

In one aspect, there is provided, a method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.

15

In one aspect, there is provided, a method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective amount of anagrelide, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered by means chosen  
20 from implants, sublingual, pregastric absorption, pessary, suppository, transdermal means, nasal spray, inhaled absorption or topical means.

In one aspect, there is provided, a method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective  
25 amount of anagrelide, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered by contacting an area of skin with a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide.

In one aspect, there is provided a method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a non-oral manner whereby the resultant overall plasma concentration for the initial 4 to 8 hours of metabolites exhibiting cardiovascular and/or inotropic side effects is lower than the overall plasma concentration for the initial 4 to 8 hours of such metabolites resulting from oral administration of an equivalent amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide.

In one aspect, there is provided, a method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective amount of anagrelide, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered to said patient transdermally or subdermally.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered transdermally.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of reservoir formulation.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a single layer formulation comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive.



In one aspect, there anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a multiple layer formulation wherein at least one layer of said multiple layer formulation comprises anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at  
5 least one adhesive.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a matrix formulation.

10 In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered subdermally.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in the form of a matrix implant  
15 formulation.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in an amount of 0.01 to 20 mg/kg/day.  
20

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in a daily dose 0.5 to 10 mg

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically  
25 acceptable salt of anagrelide is administered in a daily dose 0.5 to 3 mg.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in a daily dose 1 to 2 mg.

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered topically to the epidermis in the form of an ointment, cream or lotion.

5

In one aspect, anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a composition which further comprises at least one skin permeation enhancer.

10 In one aspect, there is provided, a method in accordance with this invention wherein administration is via a transdermal patch having a single-layer drug-in-adhesive system comprising a composition containing anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, any optional excipients, and at least one skin-contacting adhesive, which is combined with a  
15 single backing film.

In one aspect, there is provided, a method in accordance with this invention, wherein administration is via a transdermal patch having a multi-layer drug-in-adhesive system wherein: (a) said system comprises at least two distinct layers  
20 comprising at anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive, and a membrane between said at least two layers or (b) said system comprises at least two distinct layers comprising at anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive, and a single backing film.

25

In one aspect, there is provided, a method in accordance with this invention, wherein administration is via a transdermal patch having a reservoir transdermal system comprising a liquid compartment containing a solution or suspension of

anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, a release liner, and between said release liner and said liquid compartment, a semi-permeable membrane and at least one adhesive.

- 5 In one aspect, there is provided, a method in accordance with this invention, wherein administration is via a transdermal patch having a matrix system comprising a semisolid matrix containing a solution or suspension of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide which is in direct contact with a release liner, and a skin adhesion component  
10 incorporated in an overlay which forms a concentric configuration around said semisolid matrix.

- In one aspect, there is provided, a method in accordance with this invention, wherein administration is via a transdermal patch containing anagrelide,  
15 anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide intimately distributed in a matrix.

- In one aspect, there is provided, a method in accordance with this invention, wherein administration is via a transdermal patch containing 1 mg to 100 mg of  
20 anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide per patch.

- In one aspect, there is provided, in accordance with this invention, wherein administration is via a transdermal patch containing an amount of anagrelide,  
25 anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide sufficient to provide a daily dose of 0.5 to 3 mg.

In one aspect, there is provided, in accordance with this invention, wherein administration is via a transdermal patch containing a composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and an acrylic adhesive.

5

In one aspect, there is provided, a method according in accordance with this invention, wherein administration is via a transdermal patch containing having an area of  $5\text{cm}^2$  to  $100\text{cm}^2$ .

10 In one aspect, there is provided, in accordance with this invention, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered over a period of time of 1 to 7 days.

In one aspect, there is provided, in accordance with this invention, wherein  
15 anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered over a period of time of 3 to 4 days.

In one aspect, there is provided, in accordance with this invention, wherein anagrelide in base form is administered.

20

In one aspect, there is provided, a method in accordance with this invention, wherein said method comprises:

- (a) contacting said area of skin with a source of skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt  
25 of anagrelide; and
- (b) maintaining said source in material transmitting relationship to said area of skin for a period of at least 12 hours.

In one aspect, there is provided, a method in accordance with this invention, wherein said method comprises:

- (b) contacting said area of skin with a source of skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide; and
- (b) maintaining said source in material transmitting relationship to said area of skin for a period of at least 24 hours.

In one aspect, there is provided, a method of reducing the platelet count in a patient comprising administering to said patient an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.

In one aspect, there is provided, a method for reducing the side effects associated with the oral administration of anagrelide comprising administering to a patient in need thereof anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.

In one aspect, there is provided, a non-oral, pharmaceutical composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one skin permeation enhancer.

In one aspect, there is provided, a non-oral, pharmaceutical composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive.

In one aspect, there is provided, a composition according to the invention wherein at least one adhesive is an acrylic adhesive.

In one aspect, there is provided, a medical device for the transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, said device comprising:

- 5       (a) reservoir means containing a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide;
- (b) means for maintaining a said reservoir means in material transmitting relationship to a patient's skin.

10

In one aspect, there is provided, a device according to this invention, wherein said reservoir means further contains at least one skin permeation enhancer.

15       In one aspect, there is provided, a device in accordance with this invention, wherein said device is applied to a 5-100 cm<sup>2</sup> area of skin.

In one aspect, there is provided, a medical device for transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, comprising, in combination:

- 20       (a) a reservoir containing a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, and said reservoir having a skin proximal, material releasing surface area of 5-100 cm<sup>2</sup>; and
- (b) means for maintaining said reservoir in material transmitting relationship to the skin.
- 25

In one aspect, there is provided, a device in accordance with this invention, wherein said means for maintaining said reservoir in material transmitting

relationship to the skin is an amine resistant adhesive disposed in the flow path of the material from the reservoir to the skin.

In one aspect, there is provided, a device in accordance with this invention, further  
5 comprising release rate controlling means disposed in the flow path of said anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide which limits the flux of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide from said device.

10 In one aspect, there is provided, a medical device for transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, comprising:  
a backing layer, a release liner, and at least one anagrelide composition layer positioned between said backing layer and said release liner, said at least one  
15 anagrelide composition layer comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, and at least one adhesive.

This invention provides a method for treating or preventing thrombocythemia with minimal undesired effects comprising administering anagrelide transdermally or  
20 subdermally (implant).

In accordance with a further embodiment, the implant formulation is a matrix formulation.

25 In one embodiment, the thrombocythemia is associated with myeloproliferative blood disorders.

In one embodiment, the thrombocythemia is associated with essential thrombocythemia (ET), chronic myelogenous leukemia (CML), polycythemia vera (PV), agnogenic myeloid metaplasia (AMM) or sickle cell anemia(SCA).

- 5 In a further embodiment;  
The thrombocythemia is caused by ET.  
The thrombocythemia is caused by CML.  
The thrombocythemia is caused by PV.  
The thrombocythemia is caused by AMM.  
10 The thrombocythemia is caused by SCA.

In a further embodiment, the formulations can be used to reduce platelet count in a host.

- 15 There is also provided a pharmaceutically acceptable salts of the present invention. By the term pharmaceutically acceptable salts or ion pairs of anagrelide are meant those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic,  
20 salicylic, succinic, toluene-p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic, while not in themselves pharmaceutically acceptable, may be useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

- 25 Compounds claimed in the present application can be prepared by methods well know in the art, see for example US patents 3,932,407, 5,801,245 and 6,388,073.



The compounds can also be obtained from chemical supply companies such as Sigma.

Unless otherwise defined, all technical and scientific terms used herein have the  
5 same meaning as commonly understood by one of ordinary skill in the art to  
which this invention belongs. All publications, patent applications, patents, and  
other references mentioned herein are incorporated by reference in their entirety.  
In case of conflict, the present specification, including definitions, will control. In  
addition, the materials, methods, and examples are illustrative only and not  
10 intended to be limiting.

It will be appreciated that the amount of a compound of the invention required for  
use in treatment will vary not only the nature of the condition for which treatment  
is required and the age and condition of the patient and will be ultimately at the  
15 discretion of the attendant physician or veterinarian. In general however a suitable  
dose will be in the range of from about 0.01 to about 20 mg/kg of body weight per  
day, preferably in the range of 0.05 to 10 mg/kg/day, most preferably in the range  
of .04 to 5 mg/kg/day. In a further embodiment, the daily dose will be between 0.5  
and 15 mg daily. In a further embodiment, the daily dose will be between 0.5 and  
20 12 mg daily. In a further embodiment, the daily dose will be between 0.5 and 10  
mg daily. In a further embodiment, the daily dose will be between 0.5 and 5 mg  
daily. In a further embodiment, the daily dose will be between 1 and 4 mg daily. In  
a further embodiment, the daily dose will be between 0.5 and 3 mg daily. In a  
further embodiment, the daily dose will be between 1 and 3 mg daily. In a further  
25 embodiment, the daily dose will be between 1 and 2 mg daily.

In accordance with one aspect of this invention the first pass through the liver can  
be avoided by administering anagrelide by using one or more means chosen from

implants, sublingual, pregastric absorption (such as a freeze dried tablet), pessary, suppository, transdermal or topical.

Ointments and creams may, for example, be formulated with an aqueous or oily  
5 base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Transdermal patches include but are not limited to:

10

1. **Single-layer Drug-in-Adhesive system** is characterized by the inclusion of the drug directly within the skin-contacting adhesive. In this transdermal system design, the adhesive not only serves to affix the system to the skin, but also serves as the formulation foundation, containing the drug and all  
15 the excipients under a single backing film.

2. **The Multi-layer Drug-in-Adhesive** is similar to the Single-layer Drug-in-Adhesive in that the drug is incorporated directly into the adhesive. However, the multi-layer encompasses either the addition of a membrane  
20 between two distinct drug-in-adhesive layers or the addition of multiple drug-in-adhesive layers under a single backing film.

3. **The Reservoir transdermal system design** is characterized by the inclusion of a liquid compartment containing a drug solution or suspension separated from the release liner by a semi-permeable membrane and  
25 adhesive. The adhesive component of the product responsible for skin adhesion can either be incorporated as a continuous layer between the

membrane and the release liner or in a concentric configuration around the membrane

4. **The Matrix system design** is characterized by the inclusion of a semisolid matrix containing a drug solution or suspension which is in direct contact with the release liner. The component responsible for skin adhesion is incorporated in an overlay and forms a concentric configuration around the semisolid matrix.

The patches of this invention are matrix or monolithic-type laminated structures. Such transdermal patches are well known in the art. They comprise a matrix layer of the drug(s) admixed with a pressure sensitive adhesive and a backing layer. The matrix serves as both the drug reservoir and the means by which the patch is affixed to the skin. Prior to use, the patch will also include an impermeable release liner layer.

The backing layer is impermeable to the drug and other components of the matrix and defines the top face surface of the patch. It may be made of a single layer or film of polymer, or be a laminate of one or more polymer layers and metal foil. Examples of polymers suitable for use in making backing films are polyvinylchloride, polyvinylidene chloride, polyolefins such as ethylene-vinyl acetate copolymers, polyethylene, and polypropylene, polyurethane, and polyesters such as polyethylene terephthalate.

The pressure-sensitive adhesive of the matrix will normally be a solution polyacrylate, a silicone, or polyisobutylene (PIB). Such adhesives are well known in the transdermal art. See, for instance, the Handbook of Pressure Sensitive Adhesive Technology, 2nd Edition (1989) Van Nostrand, Reinhold.

Pressure sensitive solution polyacrylate adhesives are made by copolymerizing one or more acrylate monomers ("acrylate" is intended to include both acrylates and methacrylates), one or more modifying monomers, and one or more functional group-containing monomers in an organic solvent. The acrylate monomers used to  
5 make these polymers are normally alkyl acrylates of 4-17 carbon atoms, with 2-ethylhexyl acrylate, butyl acrylate, and isooctyl acrylate being preferred. Modifying monomers are typically included to alter the Tg of the polymer. Such monomers as vinyl acetate, ethyl acrylate and methacrylate, and methyl methacrylate are useful for this purpose. The functional group-containing  
10 monomer provides sites for crosslinking. The functional groups of these monomers are preferably carboxyl, hydroxy or combinations thereof. Examples of monomers that provide such groups are acrylic acid, methacrylic acid and hydroxy-containing monomers such as hydroxyethyl acrylate. The polyacrylate adhesives are preferably crosslinked using a crosslinking agent to improve their  
15 physical properties, (e.g., creep and shear resistance). The crosslinking density should be low since high degrees of crosslinking may affect the adhesive properties of the copolymer adversely. Examples of crosslinking agents are disclosed in U.S. Pat. No. 5,393,529. Solution polyacrylate pressure sensitive adhesives are commercially available under tradenames such as GELVA.TM. and  
20 DURO-TAK.TM. from 3M.

Polyisobutylene adhesives are mixtures of high molecular weight (HMW) PIB and low molecular weight (LMW) PIB. Such mixtures are described in the art, e.g., PCT/US91/02516. The molecular weight of the HMW PIB will usually be in the  
25 range of about 700,000 to 2,000,000 Da, whereas that of the LMW PIB will typically range between 35,000 to 60,000. The molecular weights referred to herein are weight average molecular weight. The weight ratio of HMW PIB to LMW PIB in the adhesive will normally range between 1:1 to 1:10. The PIB

adhesive will also normally include a tackifier such as polybutene oil and high Tg, low molecular weight aliphatic resins such as the ESCOREZ.TM. resins available from Exxon Chemical. Polyisobutylene polymers are available commercially under the tradename VISTANEX.TM. from Exxon Chemical.

5

The silicone adhesives that may be used in forming the matrix are typically high molecular weight polydimethyl siloxanes or polydimethyldiphenyl siloxanes. Formulations of silicone adhesives that are useful in transdermal patches are described in U.S. Pat. Nos. 5,232,702, 4,906,169 and 4,951,622.

10

In addition to the pressure sensitive adhesive and anagrelide, the matrix will typically contain sufficient amounts of permeation enhancers to increase the permeability of the anagrelide through the skin. Examples of skin permeation enhancers that may be included in the matrix are described above. The amount of permeation enhancer included in the matrix will depend upon the particular enhancer(s) used. In most instances then enhancer will constitute in the range of 1 to 20% by weight of the matrix.

The matrix may contain other additives depending upon the particular adhesive used. For instance, materials, such as polyvinyl pyrrolidone (PVP), that inhibit drug crystallization, hygroscopic agents that improve the duration of wear, or additives that improve the physical (e.g., cold flow) or adhesive (e.g., tack, cohesive strength) properties of the matrix may be included.

25 The patches of the invention may be fabricated using procedures known in the transdermal patch art. The procedure will generally involve formulating the matrix (i.e., mixing the adhesive, drug(s), permeation enhancer, and additives, if any), casting the matrix onto the backing or release liner layer, removing solvent from

the matrix and applying the backing/release liner layer as the case may be. As is apparent to those of skill in the art, the matrix composition having an effective amount of the drug dispersed therein can be incorporated into various transdermal constructions and therefore, applicants are not limited to the embodiments exemplified below.

In a further embodiment, anagrelide can be administered transdermally using a metered dose transdermal spray. In such system, the patient simply positions a unit comprising the active agent against the skin and activates the proper command to spray a small accurate volume of liquid comprising the active agent onto a defined area of skin. The Liquid evaporates leaving an invisible water resistant deposit from which the drug is absorbed into the body. For example technology known as the Acrux<sup>tm</sup> technology can be used.

Percutaneous or transdermal delivery of pharmacologically active agents has become feasible in recent years largely due to vehicles therefore which allow increased permeation of said agents into the body surface to which applied. Such agents which may be useful for the preparation of transdermal formulation of this invention include, but are not necessarily limited to, dimethylsulfoxide (U.S. Pat. No. 3,551,554); various 1-substituted azacycloalkan-2-ones such as azone (U.S. Pat. Nos. 4,562,075, 4,405,616, 4,326,893 and 3,989,816); sugar esters in combination with sulfoxide or phosphine oxide (U.S. Pat. Nos. 4,130,667, 4,130,643, 4,046,886, 3,952,099, and 3,896,238); lower alkyl amides (U.S. Pat. No. 3,472,931); certain aliphatic sulfoxides (U.S. Pat. No. 3,903,256); a composition containing glycerol monooleate, ethanol and isopropyl myristate (U.S. Pat. No. 4,335,115); a binary mixture of 1-dodecylazacycloheptan-2-one and a compound selected from a diol or a second N-substituted azacycloalkyl-2-one (U.S. Pat. No. 4,557,934); and polyethylene glycol monolaurate (U.S. Pat. No.

4,568,343). U.S. Pat. Nos. 3,551,554, 4,562,075, 4,405,616, 4,326,893, 3,989,816, 4,130,667, 4,130,643, 4,046,886, 3,952,099, 3,896,238, 3,472,931, 3,903,256, 4,335,115, 4,557,934, and 4,568,343.

5 It is contemplated that the transdermal or implant formulations of this invention will find utility in both humans and animals, i.e., will have both medical and veterinary applications for providing increased percutaneous absorption of the pharmaceutically active agent. As used herein, the term "percutaneous" refers to the passage of such agents through skin (typically intact).

10

The transdermal formulations of the present invention may be administered using a variety of devices which have been described in the art. For example, such devices include, but are not limited to those described in U.S. Pat. Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683, 3,742,951, 3,814,097, 3,921,636, 3,972,995, 15 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,069,307, 4,077,407, 4,201,211, 4,230,105, 4,292,299, and 4,292,303. The dosage forms of the present invention may incorporate certain pharmaceutically acceptable excipients which are conventional in the art. These include, but are not limited to, gelling agents, cream and ointment bases, and the like

20

The compound shall be present in the claimed dosage forms in an effective amount. The term "an effective amount" shall refer to an amount calculated to achieve and maintain blood levels which will bring about the desired beneficial or therapeutic effect over the period of time desired. These amounts will vary 25 depending upon the amount of pharmacologically active agent required to achieve the desired beneficial or therapeutic effect, whether one or more patches will be administered simultaneously the specific formulation of the patch, the age and condition of the patient to be treated, and the like. Such conventional dosage

titration techniques, familiar to the skilled artisan, may be utilized to determine the amount of an anagrelide present in the ultimate pharmaceutical dosage form for any specific situation. Typically, an effective amount is between about 1 mg to about 100 mg of compound per patch. More preferably, the effective amount is between  
5 about 1 mg to about 50 mg of compound. In a further embodiment, the amount of anagrelide per patch will be adjusted to provide a daily dose of about 0.5 to 2 mg daily and preferably from about 1 to 2 mg daily. The effective amount may be between about 1 mg and about 300 mg of compound for the transdermal patch formulation. The amount actually contained in the patch will depend on the factors  
10 described as well as the days of treatment provided per patch.

The pharmacologically active compound is administered by known techniques such as placing the patch containing said agent and transdermal formulation therefore on a body surface and maintaining said source on said body surface in  
15 agent and composition transmitting relation thereto.

One of the transdermal formulations of this invention utilizes ethanol, water, azone, and optionally propylene glycol to enhance the permeation of the pharmacologically anagrelide. As noted supra, azone is known to be useful for  
20 transdermal permeation enhancement and is chemically 1-dodecylazacycloheptan-2-one. Azone can be prepared as described in U.S. Pat. No. 4,316,893. The formulations can also include oleic acid.

Formulation of the claimed compositions may be achieved by conventional  
25 methods, as by the simple mixing of all components thoroughly. The artisan will appreciate that compositions containing diols other than propylene glycol and alcohols other than ethanol (i.e., 2-propanol) may find utility in transdermal anagrelide compositions as a component of the formulation. To the extent that



such formulation exhibits the characteristics of the present compositions, such formulations are considered to fall within the scope of the present invention.

The present invention provides a transdermal patch formulation comprising  
5 anagrelide as an effective amount of compound of formula, from 0.1 to 10 parts by weight azone, from 30 to 69.8 parts ethanol, 29 to 50 parts by weight water, from 0 to 30 parts by weight propylene glycol, and 1 to 5 parts by weight Klucel HF. Preferred ranges for the formulation include from 2 to 4 parts by weight azone, from 30 to 55 parts by weight ethanol, from 0 to 20 parts by weight propylene  
10 glycol, from 35 to 45 parts water, and from 2.5 to 3.5 parts Klucel HF. One further embodiment is to omit propylene glycol from the formulation.

There is provided a transdermal formulation patch wherein an effective amount of anagrelide is intimately distributed in a matrix. One such preferred matrix is a  
15 pressure sensitive adhesive.

Further, there is provided a transdermal patch formulation comprising an effective amount of anagrelide and from about 70 to 99.8% acrylate adhesive. A preferred range of acrylic adhesive comprises from about 66 to about 99.8% by weight  
20 acrylic adhesive. A further preferred range of acrylic adhesive comprises from about 70 to about 98% by weight acrylic adhesive. Another preferred range for the acrylate adhesive is from about 80 to 98 parts by weight. The acrylate adhesive is commercially available and may be purchased for example, from the National Starch and Chemical Corporation, Bridgewater, N.J. 08807, catalog number 80-  
25 1054. The acrylate adhesive typically contains 48% solids in 33% ethyl acetate/28% heptane/34% isopropanol/5% toluene by weight. A preferred range for the acrylate adhesive is from about 80 to 98 parts by weight.

Additionally, there is provided a transdermal patch formulation comprising an effective amount anagrelide, from 85 to 97 parts by weight ethanol and from 2 to 14.9 parts Klucel HF. Klucel HF is a commercially available gelling agent. For example, Klucel HF may be purchased from Aqualon. Other appropriate gelling agents can be selected by the skilled artisan. Preferred ranges for the formulation are 92 to 96 parts by weight ethanol and 2.5 to 3.5 parts Klucel HF or other appropriate gelling agent. Another preferred range for such formulations comprises from about 93 to about 95 parts by weight ethanol and from about 3 to about 3.5 parts gelling agent

10

Preferred transdermal patch formulations include but are not limited to a patch formulation comprising an effective amount of anagrelide, azone, ethanol, water, optionally propylene glycol and Klucel HF; anagrelide intimately distributed in a matrix; anagrelide and an acrylic adhesive; an anagrelide, ethanol, and Klucel HF; described herein.

15

In one embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $10\text{cm}^2$  to about  $100\text{cm}^2$ . In a further embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $30\text{cm}^2$  to about  $75\text{cm}^2$ . In a further embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $40\text{cm}^2$  to about  $60\text{cm}^2$ . In a further embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $45\text{cm}^2$  to about  $55\text{cm}^2$ . In a further embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $15\text{cm}^2$  to about  $55\text{cm}^2$ . In a further embodiment, the size of the transdermal patch or application to the skin via a delivery system is from about  $20\text{cm}^2$  to about  $40\text{cm}^2$ .

20

25

Plasma levels can be determined using gas chromatography or Liquid chromatography (LCMS-MS) methods familiar to the skilled artisan. The artisan can establish the appropriate conditions for the gas chromatographic analysis.

- 5 It shall be understood that other suitable enhancers and substances beneficial to the drug substance skin flow may preferably be included in the formulations of this invention. Such penetration enhancers such as linalool, carvacrol, thymol, citral, menthol and t-anethole. Further examples of permeation enhancers include, but are not limited to, fatty acid esters of glycerin, such as capric, caprylic,  
10 dodecyl, oleic acids; fatty acid esters of isosorbide, sucrose, polyethylene glycol ; caproyl lactic acid; laureth-2 ; laureth-2 acetate; laureth-2 benzoate; laureth-3 carboxylic acid ; laureth-4 ; laureth-5 carboxylic acid; oleth-2 ; glyceryl pyroglutamate oleate ; glyceryl oleate ; N-lauryl sarcosine; N-myristoyl sarcosine; N-octyl-2pyrrolidone ; lauraminopropionic acid; polypropylene glycol-4-laureth-2  
15 ; polypropylene glycol-4-laureth-5dimethyl lauramide ; lauramide diethanolamine (DEA). Preferred enhancers include, but are not limited to, lauryl pyroglutamate (LP), glyceryl monolaurate (GML), glyceryl monocaprylate, glyceryl monocaprate, glyceryl monooleate (GMO) and sorbitan monolaurate
- 20 In a further embodiment, the anagrelide is administered topically to the skin by means of a metered dose spray, such as disclosed in US 6,299,900, the entire disclosure of which is hereby incorporated by reference. Thus, in this embodiment, there is provided a transdermal drug delivery system comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of  
25 anagrelide, and at least one dermal penetration enhancer, wherein the dermal penetration enhancer is a safe skin-tolerant ester sunscreen, and optionally at least one volatile liquid.

According to another aspect of this embodiment, there is provided a method of administering an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide to a patient in need thereof comprising applying to a dermal surface of the patient a transdermal drug delivery  
5 system comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, and at least one dermal penetration enhancer, wherein the dermal penetration enhancer is a safe skin-tolerant ester sunscreen, and optionally at least one volatile liquid.

- 10 In accordance with another aspect of this embodiment, there is provided a non-occlusive, percutaneous or transdermal drug delivery system comprising
- (i) an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide;
  - (ii) at least one non-volatile dermal penetration enhancer; and
  - 15 (iii) at least one volatile liquid;

wherein the dermal penetration enhancer is adapted to transport anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide across a dermal surface when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the anagrelide within the  
20 surface. The dermal penetration enhancer is of low toxicity so that it is tolerated by the dermal surface.

Also, a further aspect of this embodiment provides a method of administering an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically  
25 acceptable salt of anagrelide to a patient in need thereof comprising applying to a dermal surface of the patient a transdermal drug delivery system comprising:

- (i) an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide;

(ii) at least one non-volatile dermal penetration enhancer; and

(iii) at least one volatile liquid;


wherein the dermal penetration enhancer is adapted to transport anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide across  
5 a dermal surface when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the anagrelide within the surface.

In one aspect, there is provided, a method according in accordance with this  
10 invention, wherein administration is via the transdermal drug delivery system over an area of  $5\text{cm}^2$  to  $100\text{cm}^2$ .

As described in US 6,299,900, the non-occlusive drug delivery system is preferably not supersaturated with respect to the active ingredient, in this case  
15 anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide. As the volatile liquid evaporates, the resulting non-volatile composition is rapidly driven into the dermal surface. While it is possible that as the volatile liquid evaporates, the non-volatile dermal penetration enhancer becomes supersaturated with respect to the anagrelide, it is, however, preferred  
20 that any supersaturation does not occur before transport of the resulting non-volatile composition across the epidermal surface has occurred.

Preferably, following application of the non-occlusive transdermal drug delivery system, the volatile component evaporates and the relevant area of skin becomes  
25 touch-dry, preferably within 10 minutes, more preferably within 3 minutes, most preferably within 1 minute.

Again, as described in US 6,299,900, preferred dermal penetration enhancers include esters of formula (I):



wherein

- 5  $R^1$  is hydrogen, lower alkyl, lower alkoxy, halide, hydroxy or  $\text{NR}^3\text{R}^4$ ;  
 $R^2$  is a long chain alkyl;  
 $R^3$  and  $R^4$  are each independently hydrogen, or lower alkyl, or  
 $R^3$  and  $R^4$  together with the nitrogen atom to which they are attached form  
a 5- or 6-membered heterocyclic ring;  
10  $n$  is 0 or 1; and  
 $q$  is 1 or 2.

Preferred esters of formula (I) include long chain alkyl para-aminobenzoate, long chain alkyl dimethyl-para-aminobenzoate, long chain alkyl cinnamate, long chain  
15 alkyl methoxycinnamate or long chain alkyl salicylate, for example, octyl dimethyl-para-aminobenzoate, octyl para-methoxycinnamate, octyl salicylate or isoamyl salicylate.

In addition to the dermal penetration enhancers of formula (I), known dermal  
20 penetration enhancers may be employed in the non-occlusive transdermal drug delivery system of the present invention.

Preferred volatile liquids of the present invention include safe skin-tolerant solvents such as ethanol and isopropanol. An aerosol propellant, such as dimethyl  
25 ether, may constitute a volatile liquid for the purpose of the present invention.

In a further embodiment, there is provided a combination useful for the treatment or prevention of thrombocythemia in which the transdermal formulation of the present invention further comprise anagrelide and at least one further therapeutic agent chosen from, hydroxyurea,  $P^{32}$ , busulphan, aspirin, clopidogrel, dipyridamole, ticlopidine and  $\alpha$ -interferon.

The combinations referred to above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable carrier therefore comprise a further aspect of the invention.

The individual components of such combinations may be administered either sequentially or simultaneously in separate or combined pharmaceutical formulations.

When the compound is used in combination with a second therapeutic agent, the dose of each compound may be either the same as or differ from that when the compound is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

The ratio between the compounds of the present invention and the second therapeutic agent will be readily appreciated by those skilled in the art. For example, one may use from about 1:1 to about 1: 50 of compounds of the invention:second therapeutic agent. In a further embodiment, one may use from about 1:1 to about 1:30 of compounds of the invention:second therapeutic agent. In a further embodiment, one may use from about 1:1 to about 1: 20 of compounds of the invention:second therapeutic agent. In a further embodiment, one may use from about 1:1 to about 1:15 of compounds of the invention:second therapeutic

agent. In a further embodiment, one may use from about 1:1 to about 1:10 of compounds of the invention:second therapeutic agent. In a further embodiment, one may use from about 1:1 to about 1:5 of compounds of the invention:second therapeutic agent. In a further embodiment, one may use from about 1:1 to about 1:3 of compounds of the invention:second therapeutic agent. If a further therapeutic agent is added, ratios will be adjusted accordingly.

The following examples are provided to illustrate various embodiments of the present invention and shall not be considered as limiting in scope.

10

**EXAMPLE 1****Transdermal formulation Free Base**

A 0.5 g sample of anagrelide is dissolved in a suitable amount of ethanol (200 proof). A 0.75 g sample of azone and a 5.0 g aliquot of propylene glycol are added to the ethanol mixture with stirring. A 10 g sample of water is added to the mixture. Finally, 0.75 g of Klucel is added to the mixture and stirred until the Klucel is dispersed. The mixture is allowed to stand for 24 hours. A 2.0 g sample of the formulation prepared as described herein is dispensed by syringe into a reservoir-type transdermal adhesive system.

20

**EXAMPLE 2****Transdermal Formulation without Polyethylene Glycol**

A 0.5 g sample of anagrelide is dissolved suitable amount of ethanol (200 proof). A 0.79 g sample of azone is added to the ethanol mixture with stirring. An 11.29 g sample of water is added to the mixture. Finally, 0.79 g of Klucel is added to the mixture and stirred until the Klucel is dispersed. The mixture is allowed to stand

25



for 24 hours. A 2.0 g sample of the formulation prepared as described herein is dispensed by syringe into a reservoir-type transdermal adhesive system.

### **EXAMPLE 3**

#### **5 Transdermal anagrelide in acrylic adhesive**

A 600 mg sample of anagrelide is dissolved in 41.6 g of pressure sensitive acrylic adhesive (cat. number 80-1054, National Starch and Chemical Corporation, Bridgewater, N.J. 08807). The mixture is agitated for 2 hours on a three roller  
10 mill. The mixture is coated along the length of a 3 mil thick release liner using a knife coater providing a 20 mil gap. The 20 mil gap provides an effective 20 mil thick coating of the formulation on the release liner. The sample is allowed to air dry for 24 hours. The sample is laminated on polyester backing.

### **15 EXAMPLE 4**

#### **Transdermal anagrelide in Gel**

A 1.0 g sample of anagrelide is dissolved in suitable amount of ethanol (200-proof). Then a 1.5 g sample of Klucel gelling agent is added to the solution and  
20 stirred until dispersed. The gel is allowed to stand for 24 hours. A 2.0 g sample of the formulation prepared as such is dispensed by syringe into a reservoir-type transdermal adhesive system.

### **EXAMPLE 5**

25

Duro-Tak 87-2287 is a solution polyacrylate adhesive available from National Starch and Chemical Co. Its monomer composition is: vinyl acetate, 2-ethylhexyl

acrylate, hydroxyethyl acrylate, and glycidyl methacrylate. It contains no crosslinking agent. It is available as a 50% solids solution in ethyl acetate.

Mixtures of Duro-Tak 87-2287, 0.26% aluminum acetylacetonate crosslinker, 6%  
5 anagrelide and various permeation enhancers are prepared, each system respectively comprising one of: lauryl pyroglutamate (9 wt%), glycerol monocaprylate (10 wt%), or glycerol monocaprate (5 wt%), These mixtures are cured and cast as a 100 micron thick (wet) layer onto a 3M 1022 polyester backing and dried.

10

#### EXAMPLE 6

Silicone 4202 is a polydimethylsiloxane adhesive from Dow Corning. It is mixed with anagrelide, 7% PVP (K30 from BASF; dissolved in n-propanol) and various  
15 enhancers, each system respectively comprising one of: lauryl pyroglutamate (9 wt%), glycerol monocaprylate (10 wt%), and glycerol monocaprate (5 wt%), These mixtures are cast as a 100 micron thick (wet) layer onto a 3M 1022 polyester backing and dried.

#### 20 EXAMPLE 7

PIB solutions are prepared by dissolving VISTANEX L100, Vistanex LM-MS-LC, and polybutene (Indopol H1900) in hexane. Suspensions of PVP-CLM, anagrelide and various enhancers in ethanol/ethyl acetate are prepared. The  
25 enhancers comprise one or more of the following; thioglycerol (2 – 4%wt.), oleic acid (4%wt.), methyl laurate (10 –15% wt.) and propylene glycol monolaurate (10% wt.) The PIB solution was added to the drug suspensions and the resulting mixtures were thoroughly blended. The mixtures are cast as a 10 mil thick (wet)


layer onto release liners and dried at 70 DEG C. for min. Saranex 2015 backing is laminated to the subassembly.

**EXAMPLE 8 Comparison between the oral, intr-venous and transdermal mode of administration of anagrelide in the mini-pig.**


The plasma level of anagrelide and metabolite A were measured in a mini-pig study following oral, intra-venous and transdermal administration of anagrelide.

The chemical structures of anagrelide and Metabolite A are shown below:

Anagrelide:



Metabolite A



15

The comparative bioavailability of anagrelide following oral administration of 1mg or the dermal application of a saturated solution to ~45cm<sup>2</sup> surface area of the back was assessed in three minipigs. Standard AgrylinR capsules (2x0.5mg) were administered orally to fasted animals, whereas the dermal formulation was a saturated solution of the drug in 5% (v/v) oleic acid in propylene glycol.

20

Plasma concentrations of anagrelide and its metabolites were determined by a validated LC-MS/MS assay. Pharmacokinetic parameters were calculated by non-compartmental methods using WinNonlin.

- 5 Drug administered by either route resulted in comparable exposure to anagrelide although the concentration-time profiles were markedly different. The rate of absorption was slower and the maximum plasma concentration lower (50%) following dermal application, and in further contrast to the oral route there was only a limited decline in concentrations (50%) post-peak prior to wash-off of  
10 residual dose at 24h. Rapid decline in concentrations after wash-off confirmed the conclusion that topical absorption continued throughout the period of application.

The average dermal flux was estimated to be 197ng/cm<sup>2</sup>/h.

- 15 This table summarises the study and the results  
Studies in the mini-pig (n=3)

Route/dose/formulation	C <sub>max</sub> (ng/ml) Anagrelide	C <sub>max</sub> (ng/ml) Metabolite A	AUC (ng.h/ml) Anagrelide	AUC (ng.h/ml) Metabolite A
Oral 1 mg/capsule	1.45	0.75	10.3	6.8
Intra-venous 1mg/propylene glycol	87.1	2.79	50.7	7.1
Dermal 5% OA in PG	0.69	0.27	10.8	4.1

The results are also depicted in Figure 1.

**EXAMPLE 9 PDEIII activity of metabolite A**

Inhibition of PDE III, which is present in myocardium, causes an increase in both the force and rate of cardiac contractility. These are undesirable side effects for a platelet reducing agent.

The PDE III activity of both anagrelide and metabolite A was evaluated by standard methods. Metabolite A is 40X more potent than anagrelide.

**EXAMPLE 10 Pharmacokinetics studies on anagrelide**

Previous limited clinical PK studies have shown that after oral administration of anagrelide there is a potential for significant exposure to the potent cardioactive metabolite A. While this compound undoubtedly contributes to the therapeutic platelet lowering action of anagrelide, with which it is equipotent, it is some 40 times more potent as a cardiovascular agent. A studies in total of 38 healthy male volunteers provides evidence of the extent of exposure to this metabolite as shown in the table below:

**Summary of mean pharmacokinetic parameters of anagrelide in volunteers after a single dose of the drug**

Compound	Mean Pharmacokinetic Parameters $\pm$ RSD (%)				
	Dose/N	AUC <sub>0-inf</sub> $\pm$ RSD (%) (ng·h/mL)	C <sub>max</sub> $\pm$ RSD (%) (ng/mL)	T <sub>max</sub> $\pm$ RSD (%) (hours)	t <sub>1/2</sub> $\pm$ RSD (%) (hours) <sup>1</sup>
Anagrelide	1mg (38)	11.1 $\pm$ 37.6	4.99 $\pm$ 74.4	1.3 $\pm$ 53.8	1.5 $\pm$ 49.8
Metabolite A	1mg (38)	18.0 $\pm$ 35.6	5.47 $\pm$ 56.9	1.28 $\pm$ 58.1	2.5 $\pm$ 28.7

Furthermore, data in patients suffering from myeloproliferative disease has shown at steady state even higher relative exposure to this metabolite compared to the parent drug occurs the ratio of metabolite to drug AUC being close to 3:1 This is shown in the table below:

Summary of mean pharmacokinetic parameters of BCH24426 in patients following multiple of the drug

Compound	Mean Pharmacokinetic Parameters $\pm$ RE				
	N	*AUC <sub>0-t</sub> $\pm$ RE (ng·h/mL)	C <sub>max</sub> $\pm$ RE (ng/mL)	T <sub>max</sub> $\pm$ RE (hours)	t <sub>1/2</sub> $\pm$ RE (hours)
Anagrelide	18	18.64(5.28)	5.31(1.33)	2.00(0.32)	2.89(0.73)
Metabolite A	18	48.89(17.90)	7.61(1.63)	2.25(0.28)	4.27(0.56)

\*AUC over dosage interval

#### 10 EXAMPLE 11 cardiovascular studies on Metabolite A

Earlier *in vitro* studies have already demonstrated the comparatively greater potency of metabolite A (40 fold) relative to anagrelide as an inhibitor of PDEIII. A study was conducted in a large group of dogs comparing metabolite A with the standard reference inotrope milrinone. A total of 12 animals have been used in this study which has shown metabolite A to be qualitatively like milrinone in its effects on the cardiovascular system but very considerably more potent. The essential conclusions from this work areas follows:

- Metabolite A and milrinone cause a dose-dependent increase in **heart rate**; the mean maximum *increase* in the Metabolite A group was ~66 b.p.m. and that for milrinone is ~76.
  - 5 • Metabolite A and milrinone produce a dose-dependent decrease in **mean blood pressure**, with a maximum decrease of about 30 mmHg, although Metabolite A was 10 x more potent than milrinone.
  - Metabolite A increased **(+)dP/dt max**( a measure of contractility) which was  
10 well sustained and largely dose-dependent;. Milrinone causes immediate, dose-dependent increases in **(+)dP/dt max**, but they were not well sustained. The picture with **(+)dP/dt40** was broadly similar.
  - Neither compound had a profound effects on **femoral, carotid or renal blood**  
15 **flows** i.e. blood flow to these vascular beds was largely sustained *despite* the fall in blood pressure, implying an increase in vascular conductance in these beds.
- These cardiovascular effects are those to be expected of a PDEIII inhibitor and are consistent with the adverse event profile seen in some patients treated with  
20 anagrelide and support the belief that this metabolite is indeed responsible for those observed side effects. Thus reduction of the proportion of this metabolite by transdermal administration is expected to significantly reduce the side effect profile of the drug.
- 25 **EXAMPLE 11 Further non-clinical studies to assess the effectiveness of continuous low-level exposure to anagrelide**

Earlier studies in the minipig have shown that transdermal application of anagrelide leads to lower but sustained exposure to the drug and much reduced proportion of the metabolite compared to oral administration which is potentially of benefit in minimising the CVS effects of the drug itself. However confirmation  
5 was required that the therapeutic response i.e. platelet lowering, would not be adversely affected.

In order to confirm that lower continuous level exposure - in contrast to the regular plasma higher peaks and troughs associated oral administration - were still  
10 effective in reducing blood platelets. It has been calculated that the maximum likely flux rate through human skin could give rise to a  $C_{av}$  of ~3-4ng/ml. It was therefore important to demonstrate that at this level adequate reduction in megakaryocyte formation could be achieved.

15 In order to mimic a transdermal delivery of anagrelide in culture,  $CD34^+$  cells that had been expanded for 4 days in the presence of 40 ng/ml thrombopoietin were treated for 8 additional days by continuous exposure to a concentration of 4 ng/ml anagrelide (~13 nM). Cells were harvested for analysis after 4 or 8 days of the initiation of drug treatment (day-8 and day-12 cultures, respectively). As shown in  
20 Figure 2 in day-8 cultures no effect of anagrelide could be detected. In contrast in day-12 cultures anagrelide treatment caused a statistically significant reduction in the number of megakaryocytes ( $77 \pm 5$  % of control,  $p=0.038$ ,  $n=3$ ). Similarly, in parallel cultures, a single dose of 40 ng/ml anagrelide (~133 nM) showed no effect on day-8 cultures but caused a significant inhibition in day 12-cultures ( $68 \pm 4$  %  
25 if control,  $p=0.015$ ,  $n=3$ ).



These results confirm the likely effectiveness of continuous low-level exposure in man (to just 4ng/ml) in reducing megakaryocyte production and thereby platelet numbers.

5 **Example 12 Permeation studies of anagrelide from saturated solutions of the drug in different formulations through human epidermis**

**METHODS**

**FORMULATIONS:**

10 **Saturated solutions of anagrelide were prepared in:**

1. 5% lauryl alcohol in isopropyl myristate (LA in IPM)
2. 2% oleic acid in propylene glycol (OA in PG)
3. 0.5% oleic acid in propylene glycol
4. 5% glyceryl monooleate in isopropyl myristate (GMO in IPM)
- 15 5. 5% glyceryl laurate in isopropyl myristate (GLA in IPM)
6. Formulation 1:
  - Labrasol.....53.5 %
  - Plurol Oleique..... 13.4 %
  - Labrafac Lipophile....15 %
  - 20 ➤ Propylene glycol.... 18%
7. Formulation 2:
  - Labrafil M 1944CS.....13.2 %
  - Labrafac Lipophile..... 31.8 %
  - Labrasol.....32.5 %
  - 25 ➤ Plurol oleique.....13.5 %
  - Water.....9.0
8. Transcutol
9. Isopropyl myristate (IPM)
10. Triacetin
- 30 11. 5% oleic acid (OA) in propylene glycol (PG)

12. 70:30 (v/v) dimethyl sulfoxide: propylene glycol

#### **Analytical Method Validation**

An analytical method using HPLC with UV detection was established for  
5 anagrelide. Six point calibration curves were generated over the range 0.2-2  
µg/ml were generated for each analytical run and the precision confirmed on each  
occasion by the making at least 7 replicate injections of the highest standard.  
Details of the equipment and methods used are given below.

#### 10 **HPLC Equipment**

**Column:** Apex reverse phase ODS 5µm packed column (250 x 4.6 mm)

**Pump:** Thermo Separation Products Spectra Series P100

**Autosampler:** Thermo Separation Products SpectraSERIES AS100

15 **Detector:** Thermo Separation Products SpectraSERIES UV100

**Integrator:** Thermo Separation Products ChromJet

#### **Chromatographic conditions**

*Mobile Phase:* Acetonitrile - 0.025M phosphate (KH<sub>2</sub>PO<sub>4</sub>) (50:50)

20

The mobile phase was degassed through a Millipore filter prior to use.

Column temperature: Ambient

Flow Rate: 0.5mL per minute

Injection volume: 20 $\mu$ L  
Wavelength: 255nm  
Retention time: ~6.8 minutes

- 5 pH Meter: Electronics Instruments Limited (Kent) Model no. 7065.

#### **Preparation of standard solutions for calibration**

A stock solution containing 10mg of anagrelide in 500ml acetonitrile: water (60:40) was used for to generate the calibration standards. The temperature was raised to about 50°C to ensure complete dissolution. Dilutions were made from the stock solution to give concentrations in the range 0.2-2  $\mu$ g/mL. The standards were analyzed using the HPLC procedure mentioned above. A correlation coefficient of 0.9991 was obtained.

- 10  
15 The reliability of the HPLC system was established before every run by analyzing the same concentration of the drug seven times. Typically a coefficient of variation of around 0.7% was obtained.

#### **Preparation of the human epidermis**

- 20 Human epidermis was prepared by the heat separation technique (*A.M. Kligman and E Christophers, Preparation of isolated sheets of human stratum corneum. Arch Dermatol., vol. 88, 70-73 (1963).* Water was heated to 60°C on a hotplate and the skin was immersed in the water at this temperature for 1 minute. The skin was then removed from the water and the epidermis carefully peeled off using blunt tweezers. Care was taken not to introduce any holes in this process. The
- 25

epidermal tissue was placed on a filter paper stratum corneum uppermost. The samples were then stored in freezer.

#### Diffusion cells

5 Franz-type horizontal glass diffusion cells were used. The receptor medium was thermostatted at 37°C, to represent body temperature. There will be a temperature gradient across the membrane and applied solution, but this should simulate 'in use' conditions. Under these conditions the surface temperature of the skin was 32°C.

10

The skin samples were thawed overnight before use. The epidermal membranes were cut to size and were placed between the two halves of the cells. High vacuum grease was used to seal the two compartments. The cell was clamped using a metal holder. The receptor arm was closed using glass caps to prevent  
15 evaporation. The donor compartment was occluded to prevent any donor solution evaporation

The receptor medium was first introduced and equilibrated for 1h. 1mL of the saturated solution with excess drug was applied in the donor compartment.  
20 Excess drug was used to ensure there is no depletion of the drug during the course of the experiment. The starting time was taken as the time at which the solutions were applied.

At set sampling points (12, 24, 30, 36 and 48 hours), 200µL of the receptor phase  
25 from each diffusion cell was removed for analysis of the anagrelide and replaced by an equivalent of fresh receptor phase solution pre-thermostatted to 37°C.

For each solution, six replicates were tested. A control (without any formulation applied in the donor compartment) was also examined.

## 5 **RESULTS**

Anagrelide was found to permeate, to a limited extent, from all the solutions. The permeation at 24h was found to be highest for anagrelide in ethanol ( $0.9\mu\text{g}/\text{cm}^2$ ) followed by the drug in propylene glycol ( $0.5\mu\text{g}/\text{cm}^2$ ) and then in glycerol ( $0.04\mu\text{g}/\text{cm}^2$ ).

10

Anagrelide was found to permeate, to a limited extent, from all the solutions. The permeation at 24h was found to be highest for anagrelide in 2% OA in PG ( $8.9\mu\text{g}/\text{cm}^2$ ), 5% GMO in IPM ( $5.7\mu\text{g}/\text{cm}^2$ ) and 5% GLA in IPM ( $5.2\mu\text{g}/\text{cm}^2$ ). The permeation from the suggested 'gold standard', anagrelide in  
15 70:30 DMSO: PG, was similar to the highest permeation rates achieved ( $8.4\mu\text{g}/\text{cm}^2$ ). Results are shown in the following table:

Anagrelide permeated at 24hours from different solutions		
Solvent	Amt permeated ( $\mu\text{g}/\text{cm}^2$ )	SD
Glycerol	0.04	0.03
Ethanol	0.9	0.5
PG	0.5	0.4
IPM	1.5	0.7
Transcutol	0.0	0
Triacetin	0.0	0
5% OA in PG	4.4	1
2%OA in PG	8.9	1.5
0.5% OA in PG	0.5	0.3
5% GMO in IPM	5.7	1.1
5% GLA n IPM	5.2	0.5
5% LA in IPM	0.5	0.2

Formulation 1	2.1	0.4
Formulation 2	1.5	0.6
70:30 DMSO:PG	8.4	3

Anagrelide was found to permeate, to a limited extent, from all the solutions. The amount permeated at 24h was found to be highest for anagrelide in 5% OA in PG (4.4  $\mu\text{g}/\text{cm}^2$ ) followed by the drug in IPM (1.5 $\mu\text{g}/\text{cm}^2$ ). The results are shown in

5 the following table:

Solvent	Amount permeated at 24h ( $\mu\text{g}/\text{cm}^2$ )	SD
Glycerol	0.04	0.03
Ethanol	0.9	0.5
PG	0.54	0.4
IPM	1.5	0.7
Transcutol	0	0
Triacetin	0	0
5% OA in PG	4.4	1

**What is claimed is:**

1. A method for the treatment or prevention of thrombocythemia in a patient comprising administering to said patient an effective amount of anagrelide,  
5 anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.
2. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered by means  
10 chosen from implants, sublingual, pregastric absorption, pessary, suppository, transdermal means nasal spray, inhaled absorption or topical means.
3. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered by  
15 contacting an area of skin with a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide.
4. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered to said  
20 patient transdermally or subdermally.
5. A method according to claim 4, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered transdermally.  
25
6. A method according to claim 5, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of reservoir formulation.

7. A method according to claim 5, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a single layer formulation comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive.
8. A method according to claim 5, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a multiple layer formulation wherein at least one layer of said multiple layer formulation comprises anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive.
9. A method according to claim 5, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a matrix formulation.
10. A method according to claim 4, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide administered subdermally.
11. A method according to claim 10, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in the form of a matrix implant formulation.
12. A method according to claim 1, wherein said thrombocythemia is associated with essential thrombocythemia (ET), chronic myelogenous leukemia (CML), polycythemia vera (PV), agnogenic myeloid metaplasia (AMM) or sickle cell anemia(SCA).



13. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in an amount of 0.1 to 20 mg/kg/day.

5

14. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in a daily dose 0.5 to 3 mg.

10 15. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered in a daily dose 1 to 2 mg.

16. A method according to claim 2, wherein anagrelide, anagrelide in base  
15 form, or a pharmaceutically acceptable salt of anagrelide is administered topically to the epidermis in the form of an ointment, cream or lotion.

17. A method according to claim 5, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is in the form of a  
20 composition which further comprises at least one skin permeation enhancer.

18. A method according to claim 17, wherein said at least one penetration enhancer is linalool, carvacrol, thymol, citral, menthol or t-anethole.

25

19. A method according to claim 5, wherein administration is via a transdermal patch having a single-layer drug-in-adhesive system comprising a composition containing anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, any optional excipients, and at least one skin-  
5 contacting adhesive, which is combined with a single backing film.

20. A method according to claim 5, wherein administration is via a transdermal patch having a multi-layer drug-in-adhesive system wherein:  
(a) said system comprises at least two distinct layers comprising at anagrelide,  
10 anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive, and a membrane between said at least two layers or  
(b) said system comprises at least two distinct layers comprising at anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive, and a single backing film.

15 21. A method according to claim 5, wherein administration is via a transdermal patch having a reservoir transdermal system comprising a liquid compartment containing a solution or suspension of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, a release liner, and  
20 between said release liner and said liquid compartment, a semi-permeable membrane and at least one adhesive.

22. A method according to claim 5, wherein administration is via a transdermal patch having a matrix system comprising a semisolid matrix  
25 containing a solution or suspension of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide which is in direct contact with a release liner, and a skin adhesion component incorporated in an overlay which forms a concentric configuration around said semisolid matrix.

23. A method according to claim 5, wherein administration is via a transdermal patch containing anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide intimately distributed in a matrix.
- 5
24. A method according to claim 5, wherein administration is via a transdermal patch containing 1 mg to 100 mg of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide per patch.
- 10
25. A method according to claim 5, wherein administration is via a transdermal patch containing an amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide sufficient to provide a daily dose of 0.5 to 3 mg.
- 15
26. A method according to claim 5, wherein administration is via a transdermal patch containing a composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and an acrylic adhesive.
- 20
27. A method according to claim 26, wherein said composition contains 66 to 99.8% by weight acrylate adhesive.
- 25
28. A method according to claim 5, wherein administration is via a transdermal patch containing an amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, azone, ethanol, water, optionally propylene glycol and Klucel HF.

29. A method according to claim 28, wherein administration is via a transdermal patch containing an amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, 0.1 to 10 parts by weight azone, from 30 to 69.8 parts ethanol, 29 to 50 parts by weight water, from 0 to 30 parts  
5 by weight propylene glycol, and 1 to 5 parts by weight Klucel HF.

30. A method according to claim 5, wherein administration is via a transdermal patch containing anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, ethanol, and Klucel HF.

10

31. A method according to claim 30, wherein administration is via a transdermal patch containing an amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, 85 to 97 parts by weight ethanol and 2 to 14.9 parts Klucel HF.

15

32. A method according to claim 5, wherein administration is via a transdermal patch containing having an area of  $5\text{cm}^2$  to  $100\text{cm}^2$ .

33. A method according to claim 1, wherein anagrelide, anagrelide in base  
20 form, or a pharmaceutically acceptable salt of anagrelide is administered over a period of time of 1 to 7 days.

34. A method according to claim 1, wherein anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide is administered over a  
25 period of time of 3 to 4 days.

35. A method according to claim 1, wherein anagrelide in base form is administered.

36. A method according to claim 3, wherein said method comprises:

(a) contacting said area of skin with a source of skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide; and

(b) maintaining said source in material transmitting relationship to said area of skin for a period of at least 12 hours.

37. A method of reducing the platelet count in a patient comprising administering to said patient an effective amount of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.

38. A method for reducing the side effects associated with the oral administration of anagrelide comprising administering to a patient in need thereof anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide in a manner whereby first pass liver metabolism is avoided.

39. A non-oral, pharmaceutical composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one skin permeation enhancer.

40. A composition according to claim 39, wherein said at least one penetration enhancer is linalool, carvacrol, thymol, citral, menthol or t-anethole.

41. A non-oral, pharmaceutical composition comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide and at least one adhesive.

42. A composition according to claim 41, wherein said at least one adhesive is an acrylic adhesive.

5 43. A medical device for the transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, said device comprising:

(a) reservoir means containing a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide;

10 (b) means for maintaining a said reservoir means in material transmitting relationship to a patient's skin.

44. A device according to claim 43, wherein said reservoir means further contains at least one skin permeation enhancer.

15

45. A device according to claim 43, wherein said device is applied to a 5-100 cm<sup>2</sup> area of skin.

20 46. A medical device for transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, comprising, in combination:

(a) a reservoir containing a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, and said reservoir having a skin proximal, material releasing surface area of 5-100 cm<sup>2</sup>; and

25 (b) means for maintaining said reservoir in material transmitting relationship to the skin.

47. A device according to claim 46, wherein said means for maintaining said reservoir in material transmitting relationship to the skin is an amine resistant adhesive disposed in the flow path of the material from the reservoir to the skin.

5 48. A device according to claim 46, further comprising release rate controlling means disposed in the flow path of said anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide which limits the flux of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide from said device.

10

49. A medical device for transdermal administration to a patient of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, comprising:

a backing layer, a release liner, and at least one anagrelide composition  
15 layer positioned between said backing layer and said release liner, said at least one anagrelide composition layer comprising anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide, and at least one adhesive.

50. Use of an anagrelide, anagrelide in base form, or a pharmaceutically  
20 acceptable salt of anagrelide in the manufacture of a medicament for the treatment or prevention of thrombocythemia in a patient in a manner whereby first pass liver metabolism is avoided.

51. Use according to claim 50, wherein said medicament is adapted to be  
25 administered by means chosen from implants, sublingual, pregastric absorption, pessary, suppository, transdermal means or topical means.

52. Use according to claim 50, wherein said medicament is adapted to be administered by contacting an area of skin with a skin permeable form of anagrelide, anagrelide in base form, or a pharmaceutically acceptable salt of anagrelide.



**Figure 1**

Mean plasma concentration-time profiles of anagrelide and Metabolite A after 1mg orally and after dermal application of a saturated solution for 24h.





Figure 2 Effectiveness of continuous low-level exposure to anagrelide



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/CA2004/000096

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/517

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, BIOSIS, MEDLINE, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93/09794 A (UNIV PENNSYLVANIA) 27 May 1993 (1993-05-27)  page 3, lines 28-31	1,12-15, 33-35, 37,38,50
X	US 5 306 709 A (GEWIRTZ ALAN M) 26 April 1994 (1994-04-26)  column 2, lines 27-35	1,12-15, 33-35, 37,38,50
X	STOREN, E. ET AL.: "Long-term use of anagrelide in young patients with essential thrombocythemia" BLOOD, vol. 97, no. 4, 15 February 2001 (2001-02-15), pages 863-866, XP002281471 abstract	1,12-15, 33-35, 37,38,50

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

23 June 2004

Date of mailing of the international search report

07/07/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Beyss, E

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA2004/000096

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/CA2004/000096

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9309794	A	27-05-1993	AU	3071492 A	15-06-1993
			WO	9309794 A1	27-05-1993
			US	5472944 A	05-12-1995
<hr/>					
US 5306709	A	26-04-1994	AU	3131393 A	15-06-1993
			WO	9309799 A1	27-05-1993
<hr/>					